<div><p>Cardiomyocytes (CMs) derived from human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) are functionally heterogeneous, display insufficient biological efficacy and generally possess the electrophysiological properties seen in fetal CMs. However, a homogenous population of hESC/hiPSC-CMs, with properties similar to those of adult human ventricular cells, is required for use in drug cardiotoxicity screening. Unfortunately, despite the requirement for the functional characteristics of post-mitotic beating cell aggregates to mimic the behavior of mature cardiomyocytes <em>in vitro</em>, few technological improvements have been made in this field to date. Previously, we showed that culturing hESC-CMs under ...
The progress of medical technology and scientific advances in the field of anticancer treatment have...
Human embryonic stem cell-derived cardiomyocytes (hESC-CM) have been proposed as a new model for saf...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
Cardiomyocytes (CMs) derived from human embryonic stem cells (hESCs) or human induced pluripotent st...
Cardiomyocytes (CMs) derived from human embryonic stem cells (hESCs) or human induced pluripotent st...
The epigenetic landscape and the responses to pharmacological epigenetic regulators in each human ar...
While cardiomyocytes derived from human pluripotent stem cells (hPSC-CMs) represent a promising popu...
AbstractThe field of drug testing currently needs a new integrated assay system, as accurate as syst...
AbstractThe field of drug testing currently needs a new integrated assay system, as accurate as syst...
Human-induced pluripotent stem cells (hiPSCs) are reprogrammed cells that have hallmarks similar to ...
Human-induced pluripotent stem cells (hiPSCs) are reprogrammed cells that have hallmarks similar to ...
Human-induced pluripotent stem cells (hiPSCs) are reprogrammed cells that have hallmarks similar to ...
Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise biomedicine. Global...
BACKGROUND: Human embryonic stem cells (hESCs) can be efficiently and reproducibly directed into car...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
The progress of medical technology and scientific advances in the field of anticancer treatment have...
Human embryonic stem cell-derived cardiomyocytes (hESC-CM) have been proposed as a new model for saf...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
Cardiomyocytes (CMs) derived from human embryonic stem cells (hESCs) or human induced pluripotent st...
Cardiomyocytes (CMs) derived from human embryonic stem cells (hESCs) or human induced pluripotent st...
The epigenetic landscape and the responses to pharmacological epigenetic regulators in each human ar...
While cardiomyocytes derived from human pluripotent stem cells (hPSC-CMs) represent a promising popu...
AbstractThe field of drug testing currently needs a new integrated assay system, as accurate as syst...
AbstractThe field of drug testing currently needs a new integrated assay system, as accurate as syst...
Human-induced pluripotent stem cells (hiPSCs) are reprogrammed cells that have hallmarks similar to ...
Human-induced pluripotent stem cells (hiPSCs) are reprogrammed cells that have hallmarks similar to ...
Human-induced pluripotent stem cells (hiPSCs) are reprogrammed cells that have hallmarks similar to ...
Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise biomedicine. Global...
BACKGROUND: Human embryonic stem cells (hESCs) can be efficiently and reproducibly directed into car...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
The progress of medical technology and scientific advances in the field of anticancer treatment have...
Human embryonic stem cell-derived cardiomyocytes (hESC-CM) have been proposed as a new model for saf...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...